Data Presentations

Topline Results: RZ402-201 Phase 2 Study in Patients with Diabetic Macular Edema (DME) PDF for download thumbnail
Topline Results: RZ402-201 Phase 2 Study in Patients with Diabetic Macular Edema (DME)
rize-data-call-thumb
Phase 2b Data Presentation
/wp-content/uploads/2024/05/PES-2024-Poster-Rezolute-65-x-32-in-2.pdf
Pediatric Endocrine Society (PES) 2024 Annual Meeting
/wp-content/uploads/2024/05/PES-2024-Poster-Rezolute-65-x-32-in-2.pdf
An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism:Results from the RZ358-606 (RIZE) StudyWhile 
Treatment-Of-Severe-Refractory-Hypoglycemia-Due-To-Malignant-Insulinoma-With-A-Novel-Anti-Insulin-Receptor-Antibody-thumb
Treatment Of Severe Refractory Hypoglycemia Due To Malignant Insulinoma With A Novel Anti-Insulin Receptor Antibody
RIZE Study results thumbnail
Phase 2b RIZE Data Presentation by Hüseyin Demirbilek, M.D. at ESPE 2022
Continuous-Glucose-Monitoring-(CGM)-Reveals-Undertreated-Hypoglycemia-in-Patients-with-Congenital-Hyperinsulinism-thumb
Continuous Glucose Monitoring (CGM) Reveals Undertreated Hypoglycemia in Patients with Congenital Hyperinsulinism
Single-Dose-Studies-of-RZ358-in-Patients-with-Congenital-Hyperinsulinism--Results-thumb
Single Dose Studies of RZ358 in Patients with Congenital Hyperinsulinism: Results of Population PK/PD Modeling and Simulation in Adult and Pediatric Patients
XOMA-358,-a-Novel-Treatment-for-Hyperinsulinemic-Hypoglycemia--Safety-and-Clinical-Pharmacology-from-the-First-in-Human-Trial-thumb
XOMA 358, a Novel Treatment for Hyperinsulinemic Hypoglycemia: Safety and Clinical Pharmacology from the First in Human Trial